This is a preview of subscription content, log in via an institution to check access.
Notes
2017 US dollars
Reference
Zueger PM, et al. Cost-Effectiveness Analysis of Sacubitril-Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States. Pharmacotherapy : 30 Mar 2018. Available from: URL: http://doi.org/10.1002/phar.2108
Rights and permissions
About this article
Cite this article
Sacubitril/valsartan marginally cost effective for HFrEF in USA. PharmacoEcon Outcomes News 801, 31 (2018). https://doi.org/10.1007/s40274-018-4886-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4886-2